Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
Printer-friendly version
PDF version-14 out of 15 patients (93 percent) achieved complete resolution of malignant cutaneous lesions in phase II systemic ALCL trial -
|
|
|
|---|
PDF 0.1MB 3P
Copy this html code to your website/blog and link to this press release.
More User Press Releases
- Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors, Corporate Officers and Senior
- Takeda Announces Appointment of New Directors Including New Assignment, Corporate Officers, Management of Takeda Pharmaceuticals
- Takeda to Start Internship Program for Tsinghua University of China
- Hib Vaccine TAK-816 Enters into the Phase III Clinical Trial in Japan
- Takeda filed ACTOSPatent Litigations against Generic Companies in Japan
- DATA PRESENTATIONS SHOWCASE MILLENNIUM LEADERSHIP IN PROTEIN HOMEOSTASIS AT 16CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
- Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting
- Actions Taken on Actosand Competactby French Regulatory Authorities
- Millennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical
- Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
Facebook
Twitter
del.icio.us
LinkedIn
Digg
StumbleUpon
Forward
Google
Favorite
Favorite on Technorati